Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

For successful staining of human cells, brighter fluorophore-antibody conjugates, such as PE, BV421?, or APC, are recommended.

Additional reported applications (for relevant formats) include: Western Blotting¹.

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

1. Robbins SH, et al. 2002. J. Immunol. 168:2585. (WB)
2. Robbins SH, et al. 2003. J. Immunol. 170:5876. (FC)
3. McMahon CW, et al. 2002. J. Immunol. 169:1444. (FC)

1. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
2. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
3. Wang D, et al. 2018. Immunity. 48:659. PubMed
4. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
5. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
6. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
7. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
8. Vacca F, et al. 2020. eLife. 9:e54017.. PubMed
9. Zeis P, et al. 2020. Immunity. 53:775. PubMed
10. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
11. Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed
12. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
13. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed

This product may be used for research purposes only.? It is not licensed for resale and may only be used by the buyer.? This product may not be used and is not licensed for clinical assays, where the results of such assays are provided as a diagnostic service.? If a diagnostic or therapeutic use is anticipated, then a license must be requested from the University of California.? The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California.

Subsets of NK cells, lymphokine-activated killer (LAK) cells and subsets of CD8⁺ and CD4⁺ cells.

1. Grundemann C, et al. 2006. J. Immunol. 176:1311.
2. Blaser C, et al. 1998. J. Immunol. 161:6451.
3. Huntington ND, et al. 2007. J. Immunol. 178:4764.
4. Voehringer D, et al. 2001. J. Immunol. 167:4834.